An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs TAK-164 (Primary)
- Indications Carcinoma; Gastrointestinal cancer
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 14 Nov 2019 Planned End Date changed from 29 Apr 2021 to 30 Oct 2021.
- 14 Nov 2019 Planned primary completion date changed from 29 Apr 2021 to 30 Oct 2021.
- 21 Aug 2019 Planned number of patients changed from 95 to 100.